Pulse Biosciences Framtida tillväxt
Future kriterier kontrolleras 2/6
Pulse Biosciences förväntas öka vinsten och intäkterna med 21.7% och 63.9% per år respektive medan EPS förväntas växa med 22.8% per år.
Viktig information
21.7%
Tillväxttakt i vinsten
22.80%
Tillväxttakt för EPS
| Medical Equipment vinsttillväxt | 16.9% |
| Intäkternas tillväxttakt | 63.9% |
| Framtida avkastning på eget kapital | n/a |
| Bevakning av analytiker | Low |
| Senast uppdaterad | 09 Sep 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Uppdatering av berättelse • Sep 09
PLSE: Pivotal nsPFA Trials And Early Data Will Drive Bullish Outlook
Analysts have revised their fair value estimate for Pulse Biosciences to $58 from $35, citing growing confidence in the company's differentiated nanosecond pulse field ablation platform, positive early clinical signals, and the potential impact of ongoing pivotal studies and future partnerships. Analyst Commentary on Pulse Biosciences Recent Street research on Pulse Biosciences has taken a more constructive tone, with several bullish analysts highlighting the company’s nanosecond pulsed field ablation platform and early clinical data as key supports for their valuation work.
Uppdatering av berättelse • Aug 26
PLSE: Pivotal Nanosecond Ablation Data And Partnerships Will Shape 3b Market Access
Analysts have lifted the fair value estimate for Pulse Biosciences to $45.25 from $41, citing Street research that highlights its differentiated nanosecond pulsed field ablation platform, positive early clinical data, progress in pivotal studies, and what they view as improving success probabilities following recent updates. Analyst Commentary Recent Street research on Pulse Biosciences centers on the potential of its nanosecond pulsed field ablation platform, the pace of clinical development, and how these factors feed into valuation and execution risk for investors following the story into late 2026.Uppdatering av berättelse • Aug 12
PLSE: Clinical And Regulatory Progress Will Test Access To 3b Ablation Market
The analyst price target for Pulse Biosciences has been reset from about $30.67 to $41.00, with analysts pointing to improving success probabilities for its nanosecond pulsed field ablation platform and continued clinical and regulatory progress as key drivers of their updated views. Analyst Commentary Recent Street research on Pulse Biosciences highlights both optimism around the nanosecond pulsed field ablation platform and a focus on the execution risks that come with an early stage commercial story.
Ny berättelse • Aug 07
Slower Pulsed Field Ablation Adoption Will Limit Revenue Scale And Delay Profitability
Catalysts About Pulse Biosciences Pulse Biosciences develops medical devices based on nanosecond pulsed field ablation technology for cardiac and thyroid procedures. What are the underlying business or industry changes driving this perspective?Uppdatering av berättelse • Jul 29
PLSE: Cardiac Ablation Data And Index Inclusion Will Guide Fairly Valued Outlook
Analysts have lifted their price target on Pulse Biosciences to $35 from $30, citing preliminary support for the nsPFA platform's safety and efficacy profile in cardiac ablation and its potential to address a large electrophysiology market opportunity. Analyst Commentary on Pulse Biosciences Recent Street research on Pulse Biosciences points to growing confidence in the potential of its nanosecond pulsed field ablation, or nsPFA, platform in cardiac ablation.Uppdatering av berättelse • Jul 10
PLSE: Ablation Platform And Clinical Data Will Drive Access To 3b Market
Analysts have lifted the fair value estimate for Pulse Biosciences from about $22 to roughly $30.67 per share, citing the company’s differentiated nanosecond pulsed field ablation platform and the roughly $3 billion electrophysiologists ablation market opportunity as key drivers behind a Street price target of $32. Analyst Commentary Recent Street research on Pulse Biosciences centers on the potential of its nanosecond pulsed field ablation platform and how that might justify the latest fair value estimate and price targets around US$32 per share.Uppdatering av berättelse • Jun 26
PLSE: Nanosecond Cardiac Ablation Platform Will Pursue Expanding Electrophysiology Opportunity
Analysts raised their price target on Pulse Biosciences stock from $30 to $32, citing its differentiated nanosecond pulsed field cardiac ablation platform and the $3 billion electrophysiology ablation market, which they estimate is growing 10% to 15% annually, with potential for the company to capture a meaningful share. Analyst Commentary Bullish analysts covering Pulse Biosciences emphasize that the stock is now being valued around a clearly defined opportunity in cardiac ablation, supported by a specific US$32 price target.Ny berättelse • Feb 09
Early Thyroid And Cardiac Applications Will Establish A Powerful Medical Device Platform
Catalysts About Pulse Biosciences Pulse Biosciences develops and commercializes medical devices that use proprietary nanosecond pulse field ablation technology for soft tissue and cardiac applications. What are the underlying business or industry changes driving this perspective?Analysartikel • Dec 21
Pulse Biosciences (NASDAQ:PLSE) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysartikel • Jun 12
Here's Why We're Not At All Concerned With Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Analysartikel • Feb 07
We're Not Very Worried About Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Pulse...Seeking Alpha • May 16
Pulse Biosciences Stock: Signs Of Life Following Q1 Update
Summary We recap Q1 developments from Pulse Biosciences, Inc. The FDA has cleared the company's percutaneous electrode system, while the surgical clamp device for cardiac indications is still in the preclinical trial phase. Pulse Biosciences is making progress in its commercialization strategy, but financial uncertainties may keep the stock under pressure. Read the full article on Seeking AlphaAnalysartikel • May 10
We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analysartikel • Dec 25
We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Pulse Biosciences...Analysartikel • Sep 04
We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 19 | -88 | -67 | -67 | 3 |
| 12/31/2027 | 7 | -102 | -77 | -80 | 5 |
| 12/31/2026 | 2 | -96 | -71 | -73 | 4 |
| 6/30/2026 | 1 | -80 | -61 | -61 | N/A |
| 3/31/2026 | 1 | -75 | -56 | -55 | N/A |
| 12/31/2025 | 0 | -73 | -54 | -54 | N/A |
| 9/30/2025 | 0 | -75 | -49 | -49 | N/A |
| 6/30/2025 | N/A | -68 | -45 | -44 | N/A |
| 3/31/2025 | N/A | -60 | -40 | -40 | N/A |
| 12/31/2024 | N/A | -54 | -36 | -36 | N/A |
| 9/30/2024 | N/A | -46 | -34 | -34 | N/A |
| 6/30/2024 | N/A | -44 | -36 | -35 | N/A |
| 3/31/2024 | N/A | -43 | -36 | -36 | N/A |
| 12/31/2023 | N/A | -42 | -33 | -33 | N/A |
| 9/30/2023 | 0 | -39 | -34 | -34 | N/A |
| 6/30/2023 | 0 | -47 | -35 | -34 | N/A |
| 3/31/2023 | 0 | -51 | -38 | -38 | N/A |
| 12/31/2022 | 1 | -59 | -47 | -47 | N/A |
| 9/30/2022 | 2 | -65 | -52 | -52 | N/A |
| 6/30/2022 | 2 | -61 | -55 | -54 | N/A |
| 3/31/2022 | 2 | -62 | -59 | -58 | N/A |
| 12/31/2021 | 1 | -64 | -55 | -54 | N/A |
| 9/30/2021 | 1 | -62 | -51 | -51 | N/A |
| 6/30/2021 | N/A | -61 | -46 | -46 | N/A |
| 3/31/2021 | N/A | -57 | -38 | -37 | N/A |
| 12/31/2020 | N/A | -50 | -36 | -35 | N/A |
| 9/30/2020 | N/A | -50 | -35 | -35 | N/A |
| 6/30/2020 | N/A | -49 | -35 | -35 | N/A |
| 3/31/2020 | N/A | -49 | N/A | -36 | N/A |
| 12/31/2019 | N/A | -47 | N/A | -34 | N/A |
| 9/30/2019 | N/A | -42 | N/A | -31 | N/A |
| 6/30/2019 | N/A | -41 | N/A | -30 | N/A |
| 3/31/2019 | N/A | -39 | N/A | -26 | N/A |
| 12/31/2018 | N/A | -38 | N/A | -24 | N/A |
| 9/30/2018 | N/A | -37 | N/A | -22 | N/A |
| 6/30/2018 | N/A | -34 | N/A | -18 | N/A |
| 3/31/2018 | N/A | -31 | N/A | -14 | N/A |
| 12/31/2017 | N/A | -26 | N/A | -11 | N/A |
| 9/30/2017 | N/A | -20 | N/A | -9 | N/A |
| 6/30/2017 | N/A | -15 | N/A | -8 | N/A |
| 3/31/2017 | N/A | -11 | N/A | -9 | N/A |
| 12/31/2016 | N/A | -10 | N/A | -8 | N/A |
| 9/30/2016 | N/A | -8 | N/A | -7 | N/A |
| 6/30/2016 | N/A | -6 | N/A | -6 | N/A |
| 3/31/2016 | N/A | -4 | N/A | -4 | N/A |
| 12/31/2015 | N/A | -3 | N/A | -3 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: PLSE förväntas förbli olönsam under de kommande 3 åren.
Resultat vs marknad: PLSE förväntas förbli olönsam under de kommande 3 åren.
Höga tillväxtresultat: PLSE förväntas förbli olönsam under de kommande 3 åren.
Intäkt vs marknad: PLSE s intäkter ( 63.9% per år) förväntas växa snabbare än US marknaden ( 13.6% per år).
Hög tillväxtintäkter: PLSE s intäkter ( 63.9% per år) förutspås växa snabbare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: Otillräcklig data för att avgöra om PLSE s avkastning på eget kapital förväntas bli hög om tre år
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/21 15:38 |
| Aktiekurs vid dagens slut | 2026/09/21 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Pulse Biosciences, Inc. bevakas av 6 analytiker. 5 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| William Plovanic | Canaccord Genuity |
| Keith Hinton | Freedom Capital Markets |
| Anthony Petrone | Mizuho Securities USA LLC |